MedTrace Logo

Direct Renin Inhibition and the Kidney

NCT01217736 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-02-29

No results posted yet for this study

Summary

The objective of the study is to determine the magnitude of the effect of direct renin inhibition by VTP-27999 on renal plasma flow and kidney function.

Conditions

  • Renal Function

Interventions

DRUG

aliskiren

single dose, tablet

DRUG

placebo

single dose, tablet

DRUG

VTP-27999

single dose, tablet

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • Vitae Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Norman K Hollenberg, MD, PhD · Brigham and Women's Hospital, Boston, MA

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01217736 on ClinicalTrials.gov